Promoting equitable patient representation in therapeutic clinical trials by accounting for population disease burden.
作者信息
Gimmen Megan Y, Taparra Kekoa, Deville Curtiland, Gomez Scarlett Lin
机构信息
Harvard Medical School, Boston, MA, USA.
Department of Radiation Oncology, Stanford Health Care, Palo Alto, CA, USA.
出版信息
Sci Rep. 2025 Mar 27;15(1):10591. doi: 10.1038/s41598-025-91174-x.
Abstract
摘要
相似文献
1
Promoting equitable patient representation in therapeutic clinical trials by accounting for population disease burden.通过考虑人群疾病负担，促进治疗性临床试验中患者的公平代表性。
Sci Rep. 2025 Mar 27;15(1):10591. doi: 10.1038/s41598-025-91174-x.
2
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers.肿瘤学临床试验中多样化人群的公平纳入：阻碍因素和推动因素。
ESMO Open. 2024 May;9(5):103373. doi: 10.1016/j.esmoop.2024.103373. Epub 2024 May 7.
3
Age, Race, Ethnicity, and Sex of Participants in Clinical Trials Focused on Chronic Pain.临床试验中慢性疼痛参与者的年龄、种族、民族和性别。
J Pain. 2024 Aug;25(8):104511. doi: 10.1016/j.jpain.2024.03.007. Epub 2024 Mar 16.
4
Diversity and Representation Among United States Participants in Amgen Clinical Trials.美国安进临床试验参与者的多样性和代表性。
J Racial Ethn Health Disparities. 2024 Oct;11(5):3112-3127. doi: 10.1007/s40615-023-01768-2. Epub 2023 Sep 27.
5
A Cross-Sectional Study of Sex, Race, and Ethnic Representation in Burn Registered Clinical Trials.烧伤注册临床试验中性别、种族和族裔代表性的横断面研究。
J Racial Ethn Health Disparities. 2025 Feb;12(1):576-582. doi: 10.1007/s40615-023-01897-8. Epub 2023 Dec 26.
6
Diversity and inclusion in clinical trials: Evolution throughout the development of an mRNA COVID-19 vaccine.临床试验中的多样性和包容性：mRNA COVID-19 疫苗研发过程中的演变。
Front Public Health. 2023 Apr 26;11:1113003. doi: 10.3389/fpubh.2023.1113003. eCollection 2023.
7
Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis.种族和少数民族以及老年人群体在前列腺癌临床试验中纳入情况的差异：一项荟萃分析。
JAMA Oncol. 2023 Feb 1;9(2):180-187. doi: 10.1001/jamaoncol.2022.5511.
8
A Systematic Review and Meta-Analysis Assessing Diversity and Representation in Diabetic Retinopathy Clinical Trials in the U.S.一项评估美国糖尿病视网膜病变临床试验中多样性和代表性的系统评价与荟萃分析
Ophthalmic Epidemiol. 2025 Feb 5:1-11. doi: 10.1080/09286586.2025.2457620.
9
Racial and Ethnic Representation in Atopic Dermatitis Clinical Trials.特应性皮炎临床试验中的种族和族裔代表性。
J Drugs Dermatol. 2025 Apr 1;24(4):360-364. doi: 10.36849/JDD.8705.
10
Representation in clinical trials sponsored by the United States Department of Veterans Affairs.美国退伍军人事务部赞助的临床试验中的代表性。
J Public Health (Oxf). 2025 May 29;47(2):203-206. doi: 10.1093/pubmed/fdaf003.
本文引用的文献
1
Race and Ethnicity Representation in Phase 2/3 Oncology Clinical Trial Publications: A Systematic Review.种族和民族在 2/3 期肿瘤临床试验出版物中的代表性：一项系统评价。
JAMA Health Forum. 2024 Jun 7;5(6):e241388. doi: 10.1001/jamahealthforum.2024.1388.
2
Clinical Trial Diversity-Will We Know It When We See It?临床试验的多样性——当我们看到它时我们能识别出来吗？
JAMA Oncol. 2023 Jun 1;9(6):765-767. doi: 10.1001/jamaoncol.2023.0143.
3
Why Diverse Clinical Trial Participation Matters.为何多样化的临床试验参与至关重要。
N Engl J Med. 2023 Apr 6;388(14):1252-1254. doi: 10.1056/NEJMp2215609. Epub 2023 Apr 1.
4
Demographic recruitment bias of adults in United States randomized clinical trials by disease categories between 2008 to 2019: a systematic review and meta-analysis.2008 年至 2019 年美国按疾病类别划分的成人随机临床试验的人口统计学招募偏倚：系统评价和荟萃分析。
Sci Rep. 2023 Jan 2;13(1):42. doi: 10.1038/s41598-022-23664-1.
5
Declining Representation and Reporting of Racial and Ethnic Minority Patients in Prostate Cancer Clinical Trials Despite Persistent Health Disparities-Where Progress Confronts Limitations.尽管存在持续的健康差距，但在前列腺癌临床试验中，少数族裔患者的代表性和报告率仍在下降——进步面临局限。
JAMA Oncol. 2023 Feb 1;9(2):175-177. doi: 10.1001/jamaoncol.2022.6749.
6
Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis.种族和少数民族以及老年人群体在前列腺癌临床试验中纳入情况的差异：一项荟萃分析。
JAMA Oncol. 2023 Feb 1;9(2):180-187. doi: 10.1001/jamaoncol.2022.5511.
7
Pacific Islanders Searching for Inclusion in Medicine.太平洋岛民寻求在医学领域获得包容。
JAMA Health Forum. 2021 Feb 1;2(2):e210153. doi: 10.1001/jamahealthforum.2021.0153.
8
Is representation enough or should we be targeting equitable inclusion?仅仅是代表性就足够了，还是我们应该致力于公平的包容？
Nat Rev Clin Oncol. 2022 Jul;19(7):429-430. doi: 10.1038/s41571-022-00635-z.
9
Despite The FDA's Five-Year Plan, Black Patients Remain Inadequately Represented In Clinical Trials For Drugs.尽管美国食品药品监督管理局（FDA）制定了五年计划，但在药物临床试验中，黑人患者的代表性仍然不足。
Health Aff (Millwood). 2022 Mar;41(3):368-374. doi: 10.1377/hlthaff.2021.01432.
10
Navigating Native Hawaiian and Pacific Islander Cancer Disparities From a Cultural and Historical Perspective.从文化和历史角度审视夏威夷原住民及太平洋岛民的癌症差异
JCO Oncol Pract. 2021 Mar;17(3):130-134. doi: 10.1200/OP.20.00831. Epub 2021 Jan 26.
Zotero 插件